Nirogy therapeutics, originally named as “Nirogyone Therapeutics”, is based in the biotech hub of Boston-Cambridge, MA. Founded in 2014, launched in 2019 with seed funding, Nirogy was born as a culmination of extensive search for new molecular targets in cellular metabolism.
“Nirogy” means “without illness” in Sanskrit. Our vision is to create a “curative path to end patient suffering afflicted by many diseases”. Our mission is to discover and develop innovative medicines for hard-to-treat chronic diseases such as cancer, autoimmunity, and inflammation.
Dysregulated cellular metabolism is increasingly recognized as the cause of many human diseases. The recognition by the scientific community that in pathological conditions, diverse cell types and their interactions, as opposed to single cell types, participate in the genesis and progression of disease. This concept has led us to explore the membrane-bound metabolic transporter targets that are exposed to the extracellular microenvironment. These transporter targets act as gatekeepers for intercellular communications via transport of nutrients, metabolites, etc. Under pathological conditions, these gatekeepers disrupt the homeostasis and dysregulate the normal physiological functions.
We are developing a transporter target platform that utilizes transporter biology, structural biology, and computational chemistry to dissect underlying mechanisms, guide drug design and development, and to inform patient selection strategies for the development of novel medicines to address today’s unmet medical needs.